Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)

Effects of Valsartan on Metabolic Syndrome in Patients With Hypertension

The purpose of this study is to consider the following points in patients with hypertension who complicated by metabolic syndrome for Valsartan basis treatment and an existing, standard treatment.

• Blood pressure control
• Changing of adiponectin and plasminogen activator inhibitor-1
• Influence metabolizing and cardiac function, etc.

The primary endpoints are:

• blood pressure control
• Adiponectin and plasma type1 plasminogen active inhibitor

The secondary endpoints are

• HOMA-IR
• HbA1c
• TNF-α
• IL-6
• Plasma B-type natriuretic peptide
• LVMI
• E/A ratio
• Tei-index
• Apo-J

Inclusion Criteria:

• Out patients with hypertension male and female
• Systolic blood pressure (SBP)≧140mmHg and/or diastolic blood pressure (DBP)≧90 mmHg
• Waist Surrounding diameter male≧85cm female≧90cm
• Patient who is treating either high triglyceride,low HDL,or diabetes mellitus
• Patient who is untreatment high triglyceride blood syndrome and low HDL blood syndrome,diabetes mellitus is triglceride≧150mg/dl and/or HDL cholesterol < 40 mg/dl or fasting blood glucose ≧110 mg/dl
• Untreated patients with hypertension,or patients is treated with antihypertensive agents except for ACE-I and ARB

Exclusion Criteria:

• Patient who is using ACE-I and ARB
• Serum creatinine ≧ 3 mg/dl
• Liver impairment
• History of allergy to valsartan
• Pregnant women
• Judgment by the physician that participation was unwise on the basis of patient characteristics and drug safety